Literature DB >> 7952879

(-)-Discretamine, a selective alpha 1D-adrenoceptor antagonist, isolated from Fissistigma glaucescens.

F N Ko1, J H Guh, S M Yu, Y S Hou, Y C Wu, C M Teng.   

Abstract

1. The selectivity of (-)-discretamine for alpha 1-adrenoceptor subtypes was investigated by use of functional and binding studies in rat vas deferens, spleen and aorta, and in cultured DDT1MF-2 and A10 cells. 2. In prostatic portions of rat vas deferens, the competitive antagonists (-)-discretamine, 5-methylurapidil (5-MU) and prazosin inhibited contractions to noradrenaline (NA) with pA2 values of 6.21, 8.71 and 9.27, respectively. The irreversible antagonist, chloroethylclonidine (CEC, 100 microM) failed to affect contractions to NA while nifedipine (1 microM) blocked them almost completely. 3. In rat spleen, the competitive antagonists (-)-discretamine, 5-MU and prazosin inhibited contractions to phenylephrine with pA2 values of 6.44, 7.19 and 9.45, respectively. CEC (100 microM) significantly reduced the maximum contraction to phenylephrine while nifedipine (1 microM) did not affect it. 4. In rat aorta, the competitive antagonists (-)-discretamine, 5-MU and prazosin inhibited contractions to NA with pA2 values of 7.60, 8.00 and 9.40, respectively. CEC also antagonized the contractions to NA in a competitive manner with a pA2 value of 6.10. 5. The specific binding of [3H]-prazosin to DDT1MF-2 and A10 cells was concentration-dependent and saturated at 3-5 nM with KD values of 0.24 +/- 0.02 and 0.20 +/- 0.02 nM, respectively. (-)-Discretamine,5-MU, CEC and prazosin inhibited specific [3H]-prazosin binding to DDTIMF-2 and AlO cells in a concentration-dependent manner with ICso values of 390.8 +/- 20.6, 43.6 +/- 3.9, 200.0 +/- 30.0 and 0.8 +/- 0.1 nM, respectively in DDTIMF-2 cells, and 25.0 +/- 3.2, 8.6 +/- 1.4, 1000.0 +/- 30.8 and 0.52 +/- 0.03 nM, respectively in AlO cells.6. Pretreatment of Al0 cells with CEC (10 MicroM) for 30 min and then washed out thoroughly, reduced specific [3H]-prazosin binding by 30%. The CEC-insensitive [3H]-prazosin binding was inhibited by(-)-discretamine with an IC50 value of 7.0 +/- 0.3 nM.7. 5-MU (100 nM), CEC (1 MicroM) and prazosin (10 nM) markedly inhibited NA (3 MicroM)-induced [3H]-inositol monophosphate formation in DDTIMF-2 and A1O cells, while (-)-discretamine (100 nM)inhibited NA-induced [3H]-inositol monophosphate formation only in AlO cells.8. In conclusion, (-)-discretamine is a selective alpha lD-adrenoceptor antagonist in vascular smooth muscle.Its selectivity among various al-adrenoceptor subtypes is alpha 1A: alpha1B: alpha1D =0.04:0.07:1.0.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952879      PMCID: PMC1910235          DOI: 10.1111/j.1476-5381.1994.tb13207.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Classification of phenoxybenzamine/prazosin-resistant contractions of rat spleen to norepinephrine by Schild analysis: similarities and differences to postsynaptic alpha-2 adrenoceptors.

Authors:  T P Kenakin; P J Novak
Journal:  J Pharmacol Exp Ther       Date:  1988-01       Impact factor: 4.030

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated?

Authors:  D MacKay
Journal:  J Pharm Pharmacol       Date:  1978-05       Impact factor: 3.765

4.  Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor.

Authors:  S Cotecchia; D A Schwinn; R R Randall; R J Lefkowitz; M G Caron; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Alpha 1-adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle.

Authors:  C Han; P W Abel; K P Minneman
Journal:  Nature       Date:  1987 Sep 24-30       Impact factor: 49.962

Review 6.  Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+.

Authors:  K P Minneman
Journal:  Pharmacol Rev       Date:  1988-06       Impact factor: 25.468

7.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

8.  Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists.

Authors:  G Hanft; G Gross
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

9.  Glycogen phosphorylase activation by two different alpha 1-adrenergic receptor subtypes: methoxamine selectively stimulates a putative alpha 1-adrenergic receptor subtype (alpha 1a) that couples with Ca2+ influx.

Authors:  G Tsujimoto; A Tsujimoto; E Suzuki; K Hashimoto
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

10.  Differences in the adenosine receptors modulating inositol phosphates and cyclic AMP accumulation in mammalian cerebral cortex.

Authors:  S P Alexander; D A Kendall; S J Hill
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

View more
  9 in total

1.  The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor.

Authors:  R Chess-Williams; C R Chapple; F Verfurth; A J Noble; C J Couldwell; M C Michel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Functional evidence of inverse agonism in vascular smooth muscle.

Authors:  M A Noguera; M D Ivorra; P D'Ocon
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

3.  The effect of S-(+)-boldine on the alpha 1-adrenoceptor of the guinea-pig aorta.

Authors:  S Chuliá; J Moreau; E Naline; M A Noguera; M D Ivorra; M P D'Ocón; C Advenier
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

4.  A possible structural determinant of selectivity of boldine and derivatives for the alpha 1A-adrenoceptor subtype.

Authors:  Y Madrero; M Elorriaga; S Martinez; M A Noguera; B K Cassels; P D'Ocon; M D Ivorra
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

5.  Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.

Authors:  D R Blue; D W Bonhaus; A P Ford; J R Pfister; N A Sharif; I A Shieh; R L Vimont; T J Williams; D E Clarke
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

6.  Analysis of the activity of alpha 1-adrenoceptor antagonists in rat aorta.

Authors:  P H Van der Graaf; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

7.  A novel structural framework for α(1A/D)-adrenoceptor selective antagonists identified using subtype selective pharmacophores.

Authors:  Emily S Stoddart; Sevvandi Senadheera; Iain J A MacDougall; Renate Griffith; Angela M Finch
Journal:  PLoS One       Date:  2011-05-10       Impact factor: 3.240

8.  Biocatalytic organic synthesis of optically pure (S)-scoulerine and berbine and benzylisoquinoline alkaloids.

Authors:  Joerg H Schrittwieser; Verena Resch; Silvia Wallner; Wolf-Dieter Lienhart; Johann H Sattler; Jasmin Resch; Peter Macheroux; Wolfgang Kroutil
Journal:  J Org Chem       Date:  2011-07-19       Impact factor: 4.354

9.  Scoulerine affects microtubule structure, inhibits proliferation, arrests cell cycle and thus culminates in the apoptotic death of cancer cells.

Authors:  Klara Habartova; Radim Havelek; Martina Seifrtova; Karel Kralovec; Lucie Cahlikova; Jakub Chlebek; Eva Cermakova; Nadezda Mazankova; Jana Marikova; Jiri Kunes; Lucie Novakova; Martina Rezacova
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.